Avidity Biosciences, Inc. (RNA)

NASDAQ: RNA · IEX Real-Time Price · USD

38.80

-2.48 (-6.01%)

At close: Jul 2, 2024, 4:00 PM

38.51

-0.29 (-0.75%)

After-hours: Jul 2, 2024, 7:56 PM EDT

Avidity Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	9.56	9.22	9.33	6.79	2.32	Upgrade
Revenue Growth (YoY)	3.64%	-1.09%	37.41%	192.67%	511.87%	Upgrade
Gross Profit	9.56	9.22	9.33	6.79	2.32	Upgrade
Selling, General & Admin	54.19	37.73	26.2	13.46	5.11	Upgrade
Research & Development	190.97	150.4	101.18	37.6	14.54	Upgrade
Operating Expenses	245.16	188.14	127.38	51.06	19.65	Upgrade
Operating Income	-235.6	-178.91	-118.05	-44.28	-17.33	Upgrade
Interest Expense / Income	0	0	0	0.21	7.39	Upgrade
Other Expense / Income	-23.38	-4.92	-0.04	-0.13	0.02	Upgrade
Pretax Income	-212.22	-174	-118.01	-44.36	-24.73	Upgrade
Net Income	-212.22	-174	-118.01	-44.36	-24.73	Upgrade
Shares Outstanding (Basic)	73	52	41	22	3	Upgrade
Shares Outstanding (Diluted)	73	52	41	22	3	Upgrade
Shares Change	39.97%	25.91%	91.24%	698.49%	9.53%	Upgrade
EPS (Basic)	-2.91	-3.34	-2.85	-2.05	-9.12	Upgrade
EPS (Diluted)	-2.91	-3.34	-2.85	-2.05	-9.12	Upgrade
Free Cash Flow	-123.29	-139.09	-98.55	-38.21	2.26	Upgrade
Free Cash Flow Per Share	-1.69	-2.67	-2.38	-1.76	0.83	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	Upgrade
Operating Margin	-2464.41%	-1939.65%	-1265.83%	-652.38%	-747.39%	Upgrade
Profit Margin	-2219.87%	-1886.33%	-1265.38%	-653.53%	-1066.58%	Upgrade
Free Cash Flow Margin	-1289.67%	-1507.92%	-1056.76%	-562.97%	97.24%	Upgrade
EBITDA	-207.14	-169.86	-116.68	-43.77	-17	Upgrade
EBITDA Margin	-2166.75%	-1841.49%	-1251.07%	-644.95%	-733.03%	Upgrade
Depreciation & Amortization	5.08	4.14	1.33	0.37	0.35	Upgrade
EBIT	-212.22	-174	-118.01	-44.15	-17.35	Upgrade
EBIT Margin	-2219.87%	-1886.33%	-1265.38%	-650.45%	-748.04%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).